Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI ...

Detailed price information for Eupraxia Pharmaceuticals Inc (EPRX-Q) from The Globe and Mail including charting and trades.

Progressive Web Apps, PWAs, Go Offline and Back - A Tomorrow Report by Digital Silk Development Agency

"Progressive Web Apps represent the convergence of accessibility, performance, and reliability," said Gabriel Shaoolian, CEO of Digital Silk. "Our report outlines how PWAs are evolving to provide ...

When will New Jersey’s first frost and freeze be this year? First frost date by zip code

First frost indicates the true changing of the seasons, whereas gardeners might use it as a guide for harvesting the final ...

Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for ...

Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dose planned in this trial. Patients in ...

UBCO leads creation of sustainability database to help Canadian companies

UBCO researchers and The National Research Council of Canada have teamed up to create a sustainability database that is ...